Abnormalities of the hypothalamo-pituitary-thyroid axis in the pro-opiomelanocortin deficient mouse

Regulatory Peptides

Volumn 122, Issue 3, 2004, Pages 169-172

  Martin, Niamh M ^a   Small, Caroline J ^a   Sajedi, Arshia ^a   Liao, Xiao H ^b   Weiss, Roy E ^b   Gardiner, James V ^a   Ghatei, Mohammad A ^a   Bloom, Stephen R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Obesity; Pro opiomelanocortin (POMC); Thyroid hormones; Thyroid stimulating hormone (TSH); Thyrotrophin releasing hormone (TRH)

Indexed keywords

ALPHA INTERMEDIN; LIOTHYRONINE; PROOPIOMELANOCORTIN; PROTIRELIN; THYROTROPIN; THYROXINE;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; HYPERPHAGIA; HYPOPHYSIS THYROID SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; STATISTICAL SIGNIFICANCE; WILD TYPE;

ANIMALS; HYPOTHALAMUS; MICE; MICE, KNOCKOUT; OBESITY; PITUITARY GLAND; PRO-OPIOMELANOCORTIN; THYROID GLAND; THYROTROPIN; THYROTROPIN-RELEASING HORMONE;

EID: 5644247766     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2004.06.012     Document Type: Article

References (31)

1. Fan W., Boston B.A., Kesterson R.A., Hruby V.J., Cone R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 385:1975;165-168
2. Barsh G.S., Schwartz M.W. Genetic approaches to studying energy balance: perception and integration. Nat. Rev. Genet. 3:2002;589-600
3. Yaswen L., Diehl N., Brennan M.B., Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat. Med. 5:1999;1066-1070
4. Smart J.L., Low M.J. Lack of proopiomelanocortin peptides results in obesity and defective adrenal function but normal melanocyte pigmentation in the murine C57BL/6 genetic background. Ann. N. Y. Acad. Sci. 994:2003;202-210
5. Krude H., Biebermann H., Luck W., Horn R., Brabant G., Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat. Genet. 19:1998;155-157
6. Krude H., Biebermann H., Schnabel D., Tansek M.Z., Theunissen P., Mullis P.E., et al. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J. Clin. Endocrinol. Metab. 88:2003;4633-4640
7. Ahima R.S., Prabakaran D., Mantzoros C., Qu D., Lowell B., Maratos-Flier E., et al. Role of leptin in the neuroendocrine response to fasting. Nature. 382:1996;50-252
8. Fekete C., Legradi G., Mihaly E., Huang Q.H., Tatro J.B., Rand W.M., et al. alpha-Melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. J. Neurosci. 20:2000;1550-1558
9. Fekete C., Sarkar S.R., Rand W.M., Harney J.W., Emerson C.H., Bianco A.C., et al. Agouti-related protein (AGRP) has a central inhibitory action on the hypothalamic-pituitary-thyroid (HPT) axis; comparisons between the effect of AGRP and neuropeptide Y on energy homeostasis and the HPT axis. Endocrinology. 143:2002;3846-3853
10. Kim M.S., Small C.J., Stanley S.A., Morgan D.G., Seal L.J., Kong W.M., et al. The central melanocortin system affects the hypothalamo-pituitary thyroid axis and may mediate the effect of leptin. J. Clin. Invest. 105:2000;1005-1011
11. Pohlenz J., Maqueem A., Cua K., Weiss R.E., Van Sande J., Refetoff S. Improved radioimmunoassay for measurement of mouse thyrotropin in serum: strain differences in thyrotropin concentration and thyrotroph sensitivity to thyroid hormone. Thyroid. 9:1999;1265-1271
12. Taheri S., Mahmoodi M., Opacka-Juffry J., Ghatei M.A., Bloom S.R. Distribution and quantification of immunoreactive orexin A in rat tissues. FEBS Lett. 457:1999;157-161
13. Ollmann M.M., Wilson B.D., Yang Y.K., Kerns J.A., Chen Y., Gantz I., et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science. 278:1997;135-138
14. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 88:1997;131-141
15. Graham M., Shutter J.R., Sarmiento U., Sarosi I., Stark K.L. Overexpression of Agrt leads to obesity in transgenic mice. Nat. Genet. 17:1997;273-274
16. Chen A.S., Marsh D.J., Trumbauer M.E., Frazier E.G., Guan X.M., Yu H., et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 26:2000;97-102
17. Gurney C., Hall R., Harper M., Owen S.G., Roth M., Smart G.A. Newcastle thyrotoxicosis index. Lancet. 2:1970;1275-1278
18. Weiss R.E., Xu J., Ning G., Pohlenz J., O'Malley B.W., Refetoff S. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J. 18:1999;1900-1904
19. Wilber J.F., Utiger R.D. The effect of glucocorticoids on thyrotropin secretion. J. Clin. Invest. 48:1969;2096-2103
20. Nicoloff J.T., Fisher D.A., Appleman M.D. Jr. The role of glucocorticoids in the regulation of thyroid function in man. J. Clin. Invest. 49:1970;1922-1929
21. Duick D.S., Warren D.W., Nicoloff J.T., Otis C.L., Croxson M.S. Effect of single dose dexamethasone on the concentration of serum triiodothyronine in man. J. Clin. Endocrinol. Metab. 39:1974;1151-1154
22. Chopra I.J., Williams D.E., Orgiazzi J., Solomon D.H. Opposite effects of dexamethasone on serum concentrations of 3,3′,5′-triiodothyronine (reverse T3) and 3,3′5-triiodothyronine (T3). J. Clin. Endocrinol. Metab. 41:1975;911-920
23. Williams D.E., Chopra I.J., Orgiazzi J., Solomon D.H. Acute effects of corticosteroids on thyroid activity in Graves' disease. J. Clin. Endocrinol. Metab. 41:1975;354-361
24. Emerson C.H., Seiler C.M., Alex S., Fang S.L., Mori Y., De Vito W.J. Gene expression and serum thyroxine-binding globulin are regulated by adrenal status and corticosterone in the rat. Endocrinology. 133:1993;1192-1196
25. Kakucska I., Qi Y., Lechan R.M. Changes in adrenal status affect hypothalamic thyrotropin-releasing hormone gene expression in parallel with corticotropin-releasing hormone. Endocrinology. 136:1995;2795-2802
26. Muglia L., Jacobson L., Dikkes P., Majzoub J.A. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature. 373:1995;427-432
27. Smith G.W., Aubry J.M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 20:1998;1093-1102
28. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. 19:1998;162-166
29. Topliss D.J., White E.L., Stockigt J.R. Significance of thyrotropin excess in untreated primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 50:1980;52-56
30. Barnett A.H., Donald R.A., Espiner E.A. High concentrations of thyroid-stimulating hormone in untreated glucocorticoid deficiency: indication of primary hypothyroidism? Br. Med. J. (Clin. Res. Ed.). 285:1982;172-173
31. Yoshida T., Arai T., Sugano J., Yarita H., Yanagisawa H. Isolated ACTH deficiency accompanied by 'primary hypothyroidism' and hyperprolactinaemia. Acta Endocrinol. (Copenh.). 104:1983;397-401